Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy

Robert L. Giuntoli, Daniel S. Metzinger, Connie S. DiMarco, Stephen S. Cha, Jeff A Sloan, Gary Keeney, Bobbie S. Gostout

Research output: Contribution to journalArticle

302 Citations (Scopus)

Abstract

Objective. We evaluated the predictive value of several proposed prognostic indicators and the effect of surgical management and adjuvant therapy on clinical outcome associated with leiomyosarcoma (LMS) of the uterus. Methods. A medical record search of patients treated at Mayo Clinic from 1976 through 1999 was performed using the International Classification of Diseases, Ninth Revision codes for LMS and malignant neoplasm of the uterus. Study inclusion criteria included confirmation of the diagnosis of LMS of the uterus by a pathologist at our institution. Survival curves were generated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model. A case-control investigation was also performed. Results. A total of 208 patients met study requirements. The median follow-up for survivors was 7.7 years. Multivariate analysis showed that high grade, advanced stage, and oophorectomy were associated with significantly worse disease-specific survival. Case-control investigations suggested that ovarian preservation does not adversely affect survival and that adjuvant pelvic radiation therapy does not significantly improve survival. An LMS risk-assessment index that was generated is highly predictive of survival. Conclusions. Tumor grade and stage (using modified criteria for endometrial cancer) appear to be valid prognostic indicators for LMS of the uterus. Ovarian preservation may be considered in premenopausal patients with early-stage leiomyosarcoma of the uterus. Additionally, adjuvant therapy does not appear to significantly affect survival. Finally, our highly predictive LMS risk-assessment index may be useful for counseling patients.

Original languageEnglish (US)
Pages (from-to)460-469
Number of pages10
JournalGynecologic Oncology
Volume89
Issue number3
DOIs
StatePublished - Jun 1 2003

Fingerprint

Leiomyosarcoma
Uterus
Survival
Therapeutics
Multivariate Analysis
Uterine Neoplasms
Ovariectomy
International Classification of Diseases
Endometrial Neoplasms
Proportional Hazards Models
Medical Records
Survivors
Counseling
Radiotherapy
Neoplasms

Keywords

  • Adjuvant chemotherapy
  • Adjuvant radiation therapy
  • Leiomyosarcoma
  • Oophorectomy
  • Retrospective study
  • Risk-assessment index
  • Uterine neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Retrospective review of 208 patients with leiomyosarcoma of the uterus : Prognostic indicators, surgical management, and adjuvant therapy. / Giuntoli, Robert L.; Metzinger, Daniel S.; DiMarco, Connie S.; Cha, Stephen S.; Sloan, Jeff A; Keeney, Gary; Gostout, Bobbie S.

In: Gynecologic Oncology, Vol. 89, No. 3, 01.06.2003, p. 460-469.

Research output: Contribution to journalArticle

Giuntoli, Robert L. ; Metzinger, Daniel S. ; DiMarco, Connie S. ; Cha, Stephen S. ; Sloan, Jeff A ; Keeney, Gary ; Gostout, Bobbie S. / Retrospective review of 208 patients with leiomyosarcoma of the uterus : Prognostic indicators, surgical management, and adjuvant therapy. In: Gynecologic Oncology. 2003 ; Vol. 89, No. 3. pp. 460-469.
@article{22fa870c2464431694afc2f35ebf0a02,
title = "Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy",
abstract = "Objective. We evaluated the predictive value of several proposed prognostic indicators and the effect of surgical management and adjuvant therapy on clinical outcome associated with leiomyosarcoma (LMS) of the uterus. Methods. A medical record search of patients treated at Mayo Clinic from 1976 through 1999 was performed using the International Classification of Diseases, Ninth Revision codes for LMS and malignant neoplasm of the uterus. Study inclusion criteria included confirmation of the diagnosis of LMS of the uterus by a pathologist at our institution. Survival curves were generated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model. A case-control investigation was also performed. Results. A total of 208 patients met study requirements. The median follow-up for survivors was 7.7 years. Multivariate analysis showed that high grade, advanced stage, and oophorectomy were associated with significantly worse disease-specific survival. Case-control investigations suggested that ovarian preservation does not adversely affect survival and that adjuvant pelvic radiation therapy does not significantly improve survival. An LMS risk-assessment index that was generated is highly predictive of survival. Conclusions. Tumor grade and stage (using modified criteria for endometrial cancer) appear to be valid prognostic indicators for LMS of the uterus. Ovarian preservation may be considered in premenopausal patients with early-stage leiomyosarcoma of the uterus. Additionally, adjuvant therapy does not appear to significantly affect survival. Finally, our highly predictive LMS risk-assessment index may be useful for counseling patients.",
keywords = "Adjuvant chemotherapy, Adjuvant radiation therapy, Leiomyosarcoma, Oophorectomy, Retrospective study, Risk-assessment index, Uterine neoplasms",
author = "Giuntoli, {Robert L.} and Metzinger, {Daniel S.} and DiMarco, {Connie S.} and Cha, {Stephen S.} and Sloan, {Jeff A} and Gary Keeney and Gostout, {Bobbie S.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0090-8258(03)00137-9",
language = "English (US)",
volume = "89",
pages = "460--469",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Retrospective review of 208 patients with leiomyosarcoma of the uterus

T2 - Prognostic indicators, surgical management, and adjuvant therapy

AU - Giuntoli, Robert L.

AU - Metzinger, Daniel S.

AU - DiMarco, Connie S.

AU - Cha, Stephen S.

AU - Sloan, Jeff A

AU - Keeney, Gary

AU - Gostout, Bobbie S.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Objective. We evaluated the predictive value of several proposed prognostic indicators and the effect of surgical management and adjuvant therapy on clinical outcome associated with leiomyosarcoma (LMS) of the uterus. Methods. A medical record search of patients treated at Mayo Clinic from 1976 through 1999 was performed using the International Classification of Diseases, Ninth Revision codes for LMS and malignant neoplasm of the uterus. Study inclusion criteria included confirmation of the diagnosis of LMS of the uterus by a pathologist at our institution. Survival curves were generated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model. A case-control investigation was also performed. Results. A total of 208 patients met study requirements. The median follow-up for survivors was 7.7 years. Multivariate analysis showed that high grade, advanced stage, and oophorectomy were associated with significantly worse disease-specific survival. Case-control investigations suggested that ovarian preservation does not adversely affect survival and that adjuvant pelvic radiation therapy does not significantly improve survival. An LMS risk-assessment index that was generated is highly predictive of survival. Conclusions. Tumor grade and stage (using modified criteria for endometrial cancer) appear to be valid prognostic indicators for LMS of the uterus. Ovarian preservation may be considered in premenopausal patients with early-stage leiomyosarcoma of the uterus. Additionally, adjuvant therapy does not appear to significantly affect survival. Finally, our highly predictive LMS risk-assessment index may be useful for counseling patients.

AB - Objective. We evaluated the predictive value of several proposed prognostic indicators and the effect of surgical management and adjuvant therapy on clinical outcome associated with leiomyosarcoma (LMS) of the uterus. Methods. A medical record search of patients treated at Mayo Clinic from 1976 through 1999 was performed using the International Classification of Diseases, Ninth Revision codes for LMS and malignant neoplasm of the uterus. Study inclusion criteria included confirmation of the diagnosis of LMS of the uterus by a pathologist at our institution. Survival curves were generated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox proportional hazards model. A case-control investigation was also performed. Results. A total of 208 patients met study requirements. The median follow-up for survivors was 7.7 years. Multivariate analysis showed that high grade, advanced stage, and oophorectomy were associated with significantly worse disease-specific survival. Case-control investigations suggested that ovarian preservation does not adversely affect survival and that adjuvant pelvic radiation therapy does not significantly improve survival. An LMS risk-assessment index that was generated is highly predictive of survival. Conclusions. Tumor grade and stage (using modified criteria for endometrial cancer) appear to be valid prognostic indicators for LMS of the uterus. Ovarian preservation may be considered in premenopausal patients with early-stage leiomyosarcoma of the uterus. Additionally, adjuvant therapy does not appear to significantly affect survival. Finally, our highly predictive LMS risk-assessment index may be useful for counseling patients.

KW - Adjuvant chemotherapy

KW - Adjuvant radiation therapy

KW - Leiomyosarcoma

KW - Oophorectomy

KW - Retrospective study

KW - Risk-assessment index

KW - Uterine neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0037498554&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037498554&partnerID=8YFLogxK

U2 - 10.1016/S0090-8258(03)00137-9

DO - 10.1016/S0090-8258(03)00137-9

M3 - Article

C2 - 12798712

AN - SCOPUS:0037498554

VL - 89

SP - 460

EP - 469

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -